These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Low-molecular-weight heparin in pregnancy. Kittisupamongkol W Am J Obstet Gynecol; 2009 Sep; 201(3):e12; author reply e12. PubMed ID: 19439265 [No Abstract] [Full Text] [Related]
44. [Hematochezia during anticoagulation. Pulmonary embolism as a life saver?]. Stiefelhagen P MMW Fortschr Med; 2013 Dec; 155(21-22):30. PubMed ID: 24724260 [No Abstract] [Full Text] [Related]
45. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy. Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594 [TBL] [Abstract][Full Text] [Related]
46. Management of deep vein thrombosis in cancer patients. Jahanzeb M J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S50-3. PubMed ID: 16280114 [No Abstract] [Full Text] [Related]
47. Home treatment and secondary prevention of deep vein thrombosis. Prandoni P; Mosena L Haematologica; 2001 Nov; 86(11 Suppl 2):49-53. PubMed ID: 11926778 [No Abstract] [Full Text] [Related]
48. Thromboembolism prevention in ischaemic stroke. O'Donnell M; Kearon C Lancet; 2007 Apr; 369(9571):1413-1415. PubMed ID: 17467497 [No Abstract] [Full Text] [Related]
49. Preventing venous thromboembolism in the intensive care unit: A no-brainer? Gould MK J Crit Care; 2005 Dec; 20(4):304-5. PubMed ID: 16310598 [No Abstract] [Full Text] [Related]
50. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Haas S Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477 [TBL] [Abstract][Full Text] [Related]
51. [Evidence for thrombosis prophylaxis to high-risk patients]. Själander A; Jansson JH; Bergqvist D; Eriksson H; Svensson P Lakartidningen; 2007 May 14-29; 104(20-21):1585-7. PubMed ID: 17564265 [No Abstract] [Full Text] [Related]
52. Does low molecular weight heparin cause less bleeding? Thomas DP Thromb Haemost; 1997 Dec; 78(6):1422-5. PubMed ID: 9423787 [No Abstract] [Full Text] [Related]
53. Heparins, low-molecular-weight heparins, and pentasaccharides. Dinwoodey DL; Ansell JE Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464 [TBL] [Abstract][Full Text] [Related]
54. Prolonged thromboprophylaxis with low molecular weight heparin after major abdominal surgery. Rasmussen MS Curr Opin Pulm Med; 2007 Sep; 13(5):389-92. PubMed ID: 17940482 [TBL] [Abstract][Full Text] [Related]
55. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Caine GJ; Lip GY Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973 [No Abstract] [Full Text] [Related]
56. Letter to the editor regarding cochrane reviews. Cundiff DK MedGenMed; 2001 Aug; 3(4):11. PubMed ID: 11549990 [No Abstract] [Full Text] [Related]
57. Unfractionated heparin versus low-molecular-weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Ang E Clin Nurse Spec; 2013; 27(5):229-30. PubMed ID: 23942101 [No Abstract] [Full Text] [Related]
58. Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery. Ghosh A Arch Intern Med; 1999 Jul; 159(14):1622-3. PubMed ID: 10421287 [No Abstract] [Full Text] [Related]
60. Use of low-molecular-weight heparins in the treatment and secondary prevention of cancer-associated thrombosis. Grande C; Caparro M Semin Oncol Nurs; 2005 Nov; 21(4 Suppl 1):41-9. PubMed ID: 16360897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]